Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Broad-minded or highly specialised: Which physician provides the best care for acutely Ill medical patients?

European journal of internal medicine·2026
Same author

Artificial intelligence in diagnostics and medical decision making.

European journal of internal medicine·2026
Same author

Response to the comment by Gando on the updated definition and scoring of disseminated intravascular coagulation.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Laboratory and Medicine 2.1: Care for What You Wish for.

International journal of laboratory hematology·2026
Same author

Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Organ Dysfunction in Sepsis-associated Intravascular Coagulation.

Juntendo Iji zasshi = Juntendo medical journal·2024

Related Experiment Video

Updated: May 23, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Safety of prohemostatic interventions.

Marcel Levi1

  • 1Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.m.levi@amc.uva.nl

Seminars in Thrombosis and Hemostasis
|April 19, 2012
PubMed
Summary

Pharmacological prohemostatic agents aid severe blood loss treatment but may increase rare thrombotic risks. Careful consideration of this balance is crucial for patient safety.

Area of Science:

  • Pharmacology
  • Hematology
  • Critical Care Medicine

Background:

  • Pharmacological prohemostatic agents are used as adjunctive treatments for severe blood loss.
  • Their efficacy in various clinical settings is well-established.
  • However, their procoagulant effects raise concerns about potential thrombotic complications.

Purpose of the Study:

  • To review the established efficacy of prohemostatic agents.
  • To highlight the potential risk of thrombotic complications associated with these agents.
  • To emphasize the importance of balancing benefits against risks in clinical decision-making.

Main Methods:

  • Literature review of studies on prohemostatic agents.
  • Analysis of clinical data regarding efficacy and adverse events.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma
04:20

A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma

Published on: July 28, 2020

Related Experiment Videos

Last Updated: May 23, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma
04:20

A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma

Published on: July 28, 2020

  • Synthesis of evidence on the risk-benefit profile of prohemostatic interventions.

    • Main Results:

    • Prohemostatic agents are effective in managing severe blood loss across diverse clinical scenarios.
    • Evidence suggests a potential increase in the risk of arterial and venous thromboembolism with certain prohemostatic interventions.
    • Thrombotic complications, while relatively rare, are a documented risk.

    Conclusions:

    • The use of pharmacological prohemostatic agents requires careful consideration of the potential for thrombotic complications.
    • Clinicians must weigh the benefits of controlling excessive blood loss against the risks of thromboembolism.
    • Risk-benefit assessment is paramount when employing these agents in clinical practice.